Affymax Technologies, N.v.

Affymax, Inc.

Glaxo Group Limited

Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

Peter J Schatz

Ronald W Barrett

Christian M Gates

William J Dower

Qun Yin

Steven E Cwirla

Christopher R Wagstrom

Guy Lalonde

Christopher P Holmes

Genet Zemede

David Tumelty

Larry C Mattheakis

David J Duffin

Willem P Stemmer

Nicholas C Wrighton

Bruce P England

Derek Sloan

Sherril S Haselden

Richard Wayne Hendren

Palaniappan Balasubramanian

Surekha Podduturi

Balu Palani

Millard G Cull

Jeff F Miller

Min-Jia Chen

Palani Balu

Randolph B DePrince

Gregory L Heinkel

Charles Praray Hart

Christopher John Paddon

Kevin Yin

Larry Mattheakis

Randoph B DePrince

Sunila Piplani

Barbara McEowen Merrill

Jeffrey P Northrop

Chris Holmes

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Peptides that bind to the erythropoietin receptor

Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a receptor

Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.

Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses

Labeled compounds that bind to a thrombopoietin receptor

Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a thrombopoietin receptor

The invention provides methods for identifying agents that are ligands for nuclear receptors. The methods include conducting multiplexed assays utilizing positive hybrid systems, reverse hybrid systems, direct interaction assays and other assays to screen for ligands having activity with a receptor of interest. The methods can be performed in various multiplexing formats to produce a profile that can be used to categorize a test ligand relative to known agonists and antagonists.

Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions

The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.

Use of modified tethers in screening compound libraries

Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.

Biotinylation of proteins

Growing community of inventors

Cupertino, CA, United States of America

Peter J Schatz